All Stories

  1. Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine

    Article • OncoTargets and Therapy, April 2018, Dove Medical Press

    Dr Gennaro Riccio, Rolando Paciello

  2. Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody

    Article • Journal of Immunotherapy, May 2017, Wolters Kluwer Health

    Dr Gennaro Riccio

  3. Evaluation of cardiotoxicity by 2D-speckle tracking

    Article • OncoTargets and Therapy, November 2016, Dove Medical Press

    Dr Antonio Barbieri, Dr Gennaro Riccio

  4. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors

    Article • Journal of Cardiovascular Medicine, May 2016, Wolters Kluwer Health

    Dr Gennaro Riccio

  5. RANOLAZINE AT THE END OF TRASTUZUMAB THERAPY PREVENTS LEFT VENTRICULAR DYSFUNCTION: IN VITRO AND IN VIVO STUDY

    Article • Journal of the American College of Cardiology, April 2016, Elsevier

    Dr Gennaro Riccio

  6. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

    Article • Human Vaccines & Immunotherapeutics, February 2016, Taylor & Francis

    Dr Gennaro Riccio

  7. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb

    Article • Journal of General Virology, January 2016, Society for General Microbiology

    Dr Gennaro Riccio

  8. One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1

    Article • BioMed Research International, January 2015, Hindawi Publishing Corporation

    Dr Gennaro Riccio

  9. Effects of a human compact anti-ErbB2 antibody on gastric cancer

    Article • Gastric Cancer, March 2013, Springer Science + Business Media

    Dr Gennaro Riccio, Professor Fernando Schmitt

  10. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors

    Article • Breast Cancer Research and Treatment, June 2012, Springer Science + Business Media

    Dr Gennaro Riccio

  11. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors

    Article • Breast Cancer Research and Treatment, September 2011, Springer Science + Business Media

    Dr Gennaro Riccio

  12. A Novel Human Antitumor Dimeric ImmunoRNase

    Article • Journal of Immunotherapy, June 2008, Wolters Kluwer Health

    Dr Gennaro Riccio